Corcept Therapeutics Q2 2024 Earnings Report $51.40 +0.25 (+0.49%) (As of 12/20/2024 05:51 PM ET) Earnings HistoryForecast Corcept Therapeutics EPS ResultsActual EPS$0.32Consensus EPS $0.23Beat/MissBeat by +$0.09One Year Ago EPS$0.25Corcept Therapeutics Revenue ResultsActual Revenue$163.80 millionExpected Revenue$155.14 millionBeat/MissBeat by +$8.66 millionYoY Revenue Growth+39.10%Corcept Therapeutics Announcement DetailsQuarterQ2 2024Date7/29/2024TimeAfter Market ClosesConference Call ResourcesConference CallConference Call TranscriptPress ReleaseCORT Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.>> Register for the Workshop Now Corcept Therapeutics Earnings HeadlinesCorcept Therapeutics presents results from relacorilant studyDecember 17, 2024 | markets.businessinsider.comCorcept's Relacorilant Shows Long-Term Cardiometabolic Benefits In Hypercortisolism PatientsDecember 16, 2024 | markets.businessinsider.comThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…December 21, 2024 | Crypto 101 Media (Ad)Corcept’s Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with HypercortisolismDecember 16, 2024 | finance.yahoo.comCorcept Therapeutics' FDA-Approved Korlym Hits Main Goal In Cushing's Syndrome Patients With Difficult-To-Control DiabetesDecember 13, 2024 | benzinga.comCorcept Therapeutics Diabetes Drug Korlym Meets Primary Endpoint in StudyDecember 12, 2024 | marketwatch.comSee More Corcept Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Corcept Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Corcept Therapeutics and other key companies, straight to your email. Email Address About Corcept TherapeuticsCorcept Therapeutics (NASDAQ:CORT) engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.View Corcept Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
